FindTrial
Sign In

A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan

A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220419
Enrollment
Unknown
Registered
2007-07-26
Start date
2007-07-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumor

Interventions

investigational material(s) Generic name etc : AZD2171 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Ages Eligible for Study: 20 Years - 75 Years Genders Eligible for Study: Both Inclusion Criteria: - advanced solid tumors - life expectancy is 12 weeks or longer Exclusion Criteria: - patient with uncontrolled brain metastases - patient with inappropriate laboratory test values - patient with poorly controlled hypertension

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Safety Primary Outcome Measures: - safety and tolerability Secondary Outcome Measures: - efficacy, PK—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026